1,329 calculators and references across 60 specialties, with formula confidence shown up front.
: Explanation and Clinical Context The RALES Score is a clinical tool designed to estimate the survival benefit and safety of spironolactone therapy in patients with advanced heart failure (NYHA class III–IV) and reduced ejection fraction. It is conceptually derived from the Randomized Aldactone Evaluation Study (RALES), published in the New England Journal of Medicine in 1999. The RALES trial demonstrated that addin
ABC-bleeding score (biomarker-based) echo "The ABC-bleeding score (Hijazi et al.) uses age, prior bleeding history and biomarkers (hemoglobin, high-sensitivity cardiac troponin, and GDF-15 or alternative renal markers). This model was shown to outperform traditional clinical scores in derivation/validation cohorts, but requires specific assays (hs-cTn, GDF-15). If you would like, provide numeric values for hs-cTnT (n
REHAB-HF Functional Recovery Index: Explanation and Clinical Context The REHAB-HF trial evaluated a tailored, multi-domain rehabilitation intervention in older patients hospitalized with acute decompensated heart failure (ADHF), focusing on improving physical function including endurance, mobility, strength, and balance. While the primary outcome was change in the Short Physical Performance Battery (SPPB) at 3 months
RELAX-AHF Mortality Prediction Score: Explanation and Clinical Context The RELAX-AHF (Relaxin in Acute Heart Failure) Mortality Prediction Score was developed from the RELAX-AHF trial to estimate the risk of all-cause mortality in patients with acute decompensated heart failure. This tool combines routine clinical variables available at admission to provide individualized risk estimates. Key predictors include age, b
: explanation and clinical context This page implements a proposed heuristic index to estimate the likelihood of left ventricular ejection fraction (LVEF) recovery after acute myocarditis. The index integrates several clinical and imaging features that have repeatedly been associated with myocardial recovery in published myocarditis and myocardial-injury cohorts: baseline LVEF (higher baseline LVEF associated with be
REVERSE Trial Responder Index: Explanation and Clinical Context The REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial introduced a multidimensional framework to identify cardiac resynchronization therapy (CRT) responders. It evaluated both structural reverse remodeling—quantified as ≥15% reduction in LVESVi—and clinical improvement—defined by changes in exercise capacity,
RISK-HF Readmission Score: Explanation and Clinical Context The RISK-HF Readmission Score is a prognostic model designed to estimate the risk of hospital readmission for patients discharged after an episode of heart failure decompensation. It utilises easily available clinical variables (such as age, prior heart failure hospitalisation, chronic kidney disease, COPD/OSA, atrial fibrillation, anaemia, diabetes mellitus
— explanation and context This page presents an experimental composite index adapted to reflect the primary predictors and outcomes described in ROCKET-AF and its heart-failure subgroup analyses. The ROCKET-AF trial (rivaroxaban vs warfarin) enrolled a high-risk atrial fibrillation population and reported subgroup analyses examining outcomes among patients with heart failure, demonstrating that heart failure patients